Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage
10 , e2206007 (2023)
doi: 10.1097/00004836-199700001-00029 97 WallaschekNReuterSSilkenatSWolfKNiklasCKayisogluOet al
.webp)
Improved portion control without conscious restriction
LC-MS/MS analysis of L-carnitine metabolites in blood plasma Phase I plasma samples were analyzed for TMAO within two weeks of collection using the standard addition method
US$ 26.77
US$ 23.30
US$ 28.91
US$ 20.44
